If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 19 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Oncolytic Viruses Medicine & Life Sciences
CTLA-4 Antigen Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2003 2019

  • 1062 Citations
  • 10 h-Index
  • 17 Article
  • 4 Review article
  • 1 Comment/debate
  • 1 Letter

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Rutgers, The State University

Research output: Contribution to journalArticle

Colitis
Steroids
Therapeutics
Prednisone
Melanoma

Cytokine Therapy

Silk, A. & Margolin, K., Jan 1 2019, (Accepted/In press) In : Hematology/Oncology Clinics of North America.

Rutgers, The State University

Research output: Contribution to journalArticle

Cytokines
Therapeutics
Neoplasms
Direction compound

Interferon Lambda: Toward a Dual Role in Cancer

Lasfar, A., Zloza, A., Silk, A., Lee, L. Y. & Cohen-Solal, K. A., Jan 1 2019, In : Journal of Interferon and Cytokine Research. 39, 1, p. 22-29 8 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Interferons
Neoplasms
Inflammation
Janus Kinases
Transducers

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. & McDermott, D. F., Feb 18 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 49.

Rutgers, The State University

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Interleukin-2
Melanoma
Therapeutics
Pneumonia
1 Citations (Scopus)

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

Mehnert, J., Silk, A., Lee, J. H., Dudek, L., Jeong, B. S., Li, J., Schenkel, J. M., Sadimin, E., Kane, M., Lin, H., Shih, W., Zloza, A., Chen, S. & Goydos, J., Jul 1 2018, In : Pigment Cell and Melanoma Research. 31, 4, p. 534-540 7 p.

Rutgers, The State University

Research output: Contribution to journalArticle

Riluzole
Tumors
Melanoma
Pharmacokinetics
Down-Regulation